Results 71 to 80 of about 675 (80)

Pharmacokinetics of PEGylated Recombinant Human Erythropoietin in Rats. [PDF]

J Anal Methods Chem, 2014
Cao X, Chen Z, Yu Z, Ge Y, Zeng X.
europepmc   +1 more source

Small-Molecule Trk Agonists: Where Do We Go from Here? [PDF]

J Med Chem
Thompson TS, Sefiani A, Burgess K.
europepmc   +1 more source

Unlocking Novel Therapeutic Potential of Angiotensin II Receptor Blockers. [PDF]

Int J Mol Sci
Chatzipieris FP, Mavromoustakou K, Matsoukas JM, Mavromoustakos T.   +3 more
europepmc   +1 more source

Noncanonical IFN Signaling: Mechanistic Linkage of Genetic and Epigenetic Events. [PDF]

Mediators Inflamm, 2016
Johnson HM, Ahmed CM.
europepmc   +1 more source

Erythropoietin reduces storage lesions and decreases apoptosis indices in blood bank red blood cells. [PDF]

Rev Bras Hematol Hemoter, 2016
Penuela OA, Palomino F, Gómez LA.
europepmc   +1 more source

Renal Production, Uptake, and Handling of Circulating αKlotho.

J Am Soc Nephrol, 2016
Hu MC, Shi M, Zhang J, Addo T, Cho HJ, Barker SL, Ravikumar P, Gillings N, Bian A, Sidhu SS, Kuro-o M, Moe OW.   +11 more
europepmc   +1 more source

Peptides Are Cardioprotective Drugs of the Future: The Receptor and Signaling Mechanisms of the Cardioprotective Effect of Glucagon-like Peptide-1 Receptor Agonists. [PDF]

Int J Mol Sci
Boshchenko AA, Maslov LN, Mukhomedzyanov AV, Zhuravleva OA, Slidnevskaya AS, Naryzhnaya NV, Zinovieva AS, Ilinykh PA.   +7 more
europepmc   +1 more source

A dot assay for the erythropoietin receptor using human recombinant 125I-erythropoietin

Analytical Biochemistry, 1989
A dot assay was developed for the detection of membrane receptor(s) for erythropoietin (Ep). A relatively homogeneous population of cells bearing the receptor for Ep was generated in the spleen of mice made anemic with phenylhydrazine and crude membrane extracts were prepared from spleen cell suspensions.
VANNUCCHI, ALESSANDRO MARIA, A. Grossi, D. Rafanelli, L. Vannucchi, P. R. Ferrini   +4 more
openaire   +4 more sources

Some of the next articles are maybe not open access.

Related searches:

In vivo 125I-erythropoietin pharmacokinetics are unchanged after anesthesia, nephrectomy and hepatectomy in sheep.

The Journal of Pharmacology and Experimental Therapeutics, 1996
Knowledge regarding the in vivo metabolic fate of the glycoprotein erythropoietin (EPO) is incomplete. To determine whether EPO pharmacokinetics are perturbed by ablation of the kidneys or liver or by anesthesia, EPO pharmacokinetic parameters were determined in adult sheep.
J A, Widness, P, Veng-Pedersen, R L, Schmidt, L S, Lowe, J A, Kisthard, C, Peters   +5 more
openaire   +2 more sources

Tunicamycin modulates binding of 125I-erythropoietin to Friend erythroleukemia cells.

Nihon Ketsueki Gakkai zasshi : journal of Japan Haematological Society, 1989
The effects of tunicamycin and neuraminidase treatment on the specific binding of 125I-erythropoietin to a murine erythroleukemia cell clone, B8, were investigated. Neuraminidase treatment of B8 cells did not affect the specific binding of erythropoietin, but tunicamycin treatment caused a 2.5 to 4-fold increase in the amount of 125I-erythropoietin ...
H, Fukamachi, A, Tojo, T, Saito, T, Kitamura, A, Urabe, F, Takaku   +5 more
openaire   +1 more source